Amneal Pharmaceuticals, Inc.

Listed Company

AMRXCIK 0001723128NasdaqLarge AcceleratedPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

$3.02B

Net Income

$72.06M

Total Assets

$3.68B

Equity

$-70.79M

Shares Out

314.63M

Op. Cash Flow

$339.99M

Business

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. It offers prescription generic pharmaceuticals, sterile injectables, biosimilars, and branded specialty products focused on central nervous system and endocrine disorders, as well as distribution and re-packaging services. The company operates through three reportable segments: Affordable Medicines (retail generics, injectables, biosimilars), Specialty (branded pharmaceuticals), and AvKARE (government and institutional distribution). Amneal conducts operations principally in the U.S., India and Ireland and distributes products via wholesalers, distributors, retailers, hospitals, specialty pharmacies and government contracts.

Summary from filing dated 2025-02-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenue	3,019	2,794	2,394	2,212	2,094
Cost of goods sold	1,905	1,774	1,573	1,428	1,325
Gross profit	1,113	1,020	821	785	769
Selling, general and administrative	527	476	430	400	366
Research and development	186	191	164	196	202
In-process research and development impairment charges	0	0	31	13	710,000
Intellectual property legal development expenses	8	6	4	4	—
Restructuring and other charges	4	2	2	1	2
(Credit) charges related to legal matters, net	−390,000	97	2	270	25
Other operating income	−5	−930,000	−16	−4	0
Operating income	394	249	204	−95	153
Interest expense, net	−241	−259	−211	−158	−136
Foreign exchange gain (loss), net	8	−7	2	−12	−355,000
Loss on refinancing	−31	0	−41	−291,000	0
Increase in tax receivable agreement liability	−7	−51	−3	−600,000	—
Other income, net	17	12	8	18	15
Total other expense, net	−255	−304	−245	−153	−121
Income (loss) before income taxes	139	−55	−40	−248	31
Provision for income taxes	11	19	8	7	11
Net income (loss)	128	−74	−49	−255	20
Less: Net income attributable to non-controlling interests	−56	−43	−35	125	−10
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.	72	−117	−84	—	—
Basic (in dollars per share)	0.23	−0.38	−0.48	−0.86	0.07
Diluted (in dollars per share)	0.22	−0.38	−0.48	−0.86	0.07
Basic (in shares)	313	309	176	151	149
Diluted (in shares)	325	309	176	151	152

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	282	111	92	26	248
Restricted cash	29	8	8	9	9
Inventories	606	612	581	531	489
Prepaid expenses and other current assets	98	81	83	104	110
Total current assets	1,911	1,588	1,378	1,412	1,520
Property, plant and equipment, net	443	425	448	470	514
Goodwill	595	597	599	599	593
Intangible assets, net	563	732	890	1,096	1,167
Operating lease right-of-use assets	54	42	43	56	60
Other assets	58	60	56	103	21
Total assets	3,678	3,501	3,473	3,799	3,940
Current portion of liabilities for legal matters	43	32	77	107	58
Revolving credit facility	0	100	179	60	0
Current portion of long-term debt, net	7	224	34	30	31
Total current liabilities	882	1,130	847	753	677
Long-term debt, net	2,565	2,162	2,386	2,592	2,680
Liabilities for legal matters - long term	72	85	300,000	—	—
Total long-term liabilities	2,791	2,416	2,565	2,838	2,879
Commitments and contingencies (Notes 4, 19 and 22)	—	—	—	—	—
Redeemable non-controlling interests	77	65	41	25	17
Preferred stock, $0.01 par value, 2,000 shares authorized at December 31, 2025 and 2024; none issued at both December 31, 2025 and 2024	0	0	0	0	0
Additional paid-in capital	572	560	539	692	658
Stockholders accumulated deficit	−535	−607	−490	−406	−276
Accumulated other comprehensive loss	−111	−66	−32	10	−25
Total Amneal Pharmaceuticals, Inc. stockholders deficiency	−71	−109	20	298	360
Non-controlling interests	−535,000	−245,000	230,000	−114	7
Total stockholders deficiency	−71	−110	20	184	367
Total liabilities and stockholders deficiency	3,678	3,501	3,473	3,799	3,940

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	224	236	229	240	233
Unrealized foreign currency (gain) loss	−7	7	−768,000	15	175,000
Amortization of debt issuance costs and discount	22	29	12	9	9
Reclassification of cash flow hedge	1	−26	−3	—	—
Intangible asset impairment charges	23	920,000	67	24	23
Change in fair value of contingent consideration	0	0	−14	731,000	200,000
Stock-based compensation	32	28	27	32	28
Inventory provision	86	97	75	51	55
Other operating charges and credits, net	5	2	10	9	6
Trade accounts receivable, net	−121	−163	126	−80	−24
Inventories	−87	−131	−126	−102	−49
Prepaid expenses, other current assets and other assets	−19	−959,000	38	10	−22
Related party receivables	−13,000	482,000	−490,000	646,000	7
Accounts payable, accrued expenses and other liabilities	21	235	−94	110	−44
Related party payables	931,000	54	10	2	−2
Net cash provided by operating activities	340	295	346	65	242
Purchases of property, plant and equipment	−70	−52	−43	−46	−48
Acquisition of intangible assets	−16	−15	−22	−42	−2
Deposits for future acquisition of property, plant, and equipment	−29	−8	−4	−2	−3
Proceeds from sale of property, plant, equipment and other	2	0	0	—	—
Proceeds from sale of subsidiary	0	12	0	0	—
Net cash used in investing activities	−112	−63	−69	−174	−194
Proceeds from issuance of debt	2,695	0	218	0	0
Payments of principal on debt, revolving credit facility, financing leases and other	−2,812	−189	−414	−123	−78
Payments of deferred financing, refinancing costs and debt extinguishment costs	−75	−71,000	−162	−2	—
Borrowings on revolving credit facility	218	48	219	85	0
Proceeds from exercise of stock options	2	1	451,000	662,000	853,000
Employee payroll tax withholding on restricted stock unit and performance stock unit vesting	−22	−8	−2	−4	−3
Tax and other distributions to non-controlling interests	−44	−20	−71	−18	−57
Payment of principal on notes payable - related party	0	−44	0	0	−1
Proceeds from alliance party	6	0	0	—	—
Net cash used in financing activities	−32	−212	−213	−107	−138
Effect of foreign exchange rate on cash	−2	−999,000	65,000	−6	102,000
Net increase in cash, cash equivalents, and restricted cash	195	19	64	−222	−90
Cash paid for interest	198	264	193	143	122
Cash paid, net for income taxes	21	15	2	13	−16
Payable for acquisition of product rights and licenses	9	4	2	0	300,000
Loan for land purchase - related party	476,000	0	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro